Abstract:This study investigated the efficacy of the prophylactic human papillomavirus (HPV) vaccine, which was initiated between 2009 and 2013 in Japan. The study involved 1529 eligible women aged 16–39 years who visited 11 outpatient clinics in Japan for various reasons. These patients underwent HPV genotype analysis and a Pap test of cervical cell samples. A total of 299 women (19.6%) had received the prophylactic HPV vaccine (bivalent:quadrivalent vaccine ratio = 2:1). Of the 5062 participants in the Japanese Human Papillomavirus Disease Education and Research Survey (J‐HERS 2011), which was conducted in the pre‐vaccination era, 3236 eligible participants were included as controls. In this study (J‐HERS 2021), the highest rate of HPV vaccination (53%) was observed in patients aged 22–27 years. Vaccinated individuals exhibited a 49% rate of protection against low‐grade intraepithelial lesions (LSILs) and atypical squamous cells, not excluding high‐grade squamous intraepithelial lesions (ASCH) or worse (LSIL/ASCH+), and a 100% rate of protection against high‐grade squamous intraepithelial lesions (HSILs) or worse (HSIL+). Significant reductions in HPV16 (95%) and HPV18 (100%) infections were noted, but no differences were observed in HPV6 and HPV11 infections. The prevalences of HPV51 and HPV59 increased with vaccination, although these changes were not confirmed in the comparative study with J‐HERS 2011. Comparing the prevaccination (J‐HERS 2011) and postvaccination (J‐HERS 2021) periods, 43%, 51%, 88%, and 62% reductions in HPV16, HPV18, HPV16/18, and HPV31/58 infection rates were observed, respectively. Similarly, 62% and 71% reductions in LSIL/ASCH+ and HSIL+ rates were noted, respectively. There were 88% and 87% reductions in LSIL/ASCH+ and HSIL+ rates in 16–21‐ and 28–33‐year‐old patients, respectively. Bivalent or quadrivalent vaccines provided 100% protection against high‐grade squamous cell lesions (suggestive of CIN2 or CIN3) in young women aged <39 years at 9–12 years after initiation of Japan's first nationwide HPV vaccination program. Cross‐protection against HPV31 and HPV58 is likely to occur, although some HPV‐type replacements are inconsistent across vaccination regimens. This demonstrates the effectiveness of the HPV vaccine. However, continuous monitoring of cervical cancer and precancer is necessary in younger generations (born 1997–2007), who were rarely vaccinated due to the prolonged suspension of the vaccine recommendations in Japan.

Human papillomavirus (HPV) vaccination in Japan

HPV Vaccine Issues in Japan: A review of our attempts to promote the HPV vaccine and to provide effective evaluation of the problem through social-medical and behavioral-economic perspectives

Underlying background of the current trend of increasing HPV vaccination coverage in Japan

Even though active recommendation for HPV vaccination has restarted, Japan's rates have not recovered

Effectiveness of prophylactic HPV vaccines against cervical abnormalities and HPV infection in Japan: The J‐HERS 2021 multicenter study

Trends and future projections of cervical cancer-related outcomes in Japan: What happens if the HPV vaccine program is not implemented?

Effectiveness of catch‐up and routine program of the 9‐valent vaccine on cervical cancer risk reduction in Japan

The efficacy of human papillomavirus vaccination in young Japanese girls: the interim results of the OCEAN study

Effectiveness of HPV vaccination against the development of high-grade cervical lesions in young Japanese women

Three‐year questionnaire study on human papillomavirus vaccination targeting new female college school students: Follow‐up to a 2021 report to reveal the impact of a policy change in Japan

Knowledge and awareness of human papillomavirus (HPV) influence HPV vaccination uptake among the catch-up generation in Japan

Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study

Reduction in HPV16/18 prevalence among young women with high‐grade cervical lesions following the Japanese HPV vaccination program

Human papillomavirus vaccine to prevent CIN3 or worse (CIN3+): A nationwide case–control study in Japan

The impact of alternate HPV vaccination and cervical screening strategies in Japan: a cost-effectiveness analysis

Understanding Public Attitudes Towards Human Papillomavirus Vaccination in Japan: Insights from Social Media Stance Analysis Using Large Language Models

Unlocking Japan's cervical cancer prevention deadlock

Questionnaire survey on cervical cancer screening and HPV awareness among patients at a local cancer center in Japan

Estimation of self‐funded human papillomavirus vaccine recipients from Japan's previously assumed "unvaccinated generation"

A Review of Human Papillomavirus Vaccination and Associated Ethical Concerns

Barriers to and Facilitators of Human Papillomavirus Vaccination among People Aged 9 to 26 Years: A Systematic Review